Hidradenitis suppurativa: Difference between revisions

* [[Biologics]]: Studies have supported that various biologics have a positive effect on HS lesions.<ref>{{cite journal | vauthors = Haslund P, Lee RA, Jemec GB | title = Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors | journal = Acta Dermato-Venereologica | volume = 89 | issue = 6 | pages = 595–600 | date = November 2009 | pmid = 19997689 | doi = 10.2340/00015555-0747 | doi-access = free }}</ref> Specifically [[adalimumab]] at weekly intervals is useful.<ref>{{cite journal | vauthors = Ingram JR | title = Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review | journal = JAMA Dermatology | volume = 153 | issue = 5 | pages = 458–459 | date = May 2017 | pmid = 28355440 | doi = 10.1001/jamadermatol.2017.0432 }}</ref> Adalimumab and Secukinumab<ref>{{cite web | url=https://www.novartis.com/us-en/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade | title=FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade }}</ref><ref>{{cite web | url=https://www.cosentyx.com/hidradenitis-suppurativa/signs-and-symptoms | title=HS Signs and Symptoms &#124; COSENTYX® (Secukinumab) }}</ref> are both approved by the FDA for the treatment of HS as of 2023.

* Topical [[isotretinoin]] is usually ineffective in people with HS, and is more commonly known as a medication for the treatment of [[acne vulgaris]]. Individuals affected by HS who responded to isotretinoin treatment tended to have milder cases of the condition.<ref>{{cite journal | vauthors = Nickle SB, Peterson N, Peterson M | title = Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin | journal = The Journal of Clinical and Aesthetic Dermatology | volume = 7 | issue = 4 | pages = 22–34 | date = April 2014 | pmid = 24765227 | pmc = 3990537 }}</ref>

 

=== Surgery ===